What is Oxford Nanopore Technologies Sloan Ratio %?
Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Oxford Nanopore Technologies's Sloan Ratio %
For the Biotechnology subindustry, Oxford Nanopore Technologies's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oxford Nanopore Technologies's Sloan Ratio % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Oxford Nanopore Technologies's Sloan Ratio % distribution charts can be found below:
* The bar in red indicates where Oxford Nanopore Technologies's Sloan Ratio % falls into.
Oxford Nanopore Technologies Sloan Ratio % Calculation
Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.
For company reported semi-annually, GuruFocus uses latest two semi-annual data as the TTM data.
Oxford Nanopore Technologies's Net Income for the trailing twelve months (TTM) ended in Jun. 2024 was -84.408 (Dec. 2023 ) + -74.652 (Jun. 2024 ) = £-159.1 Mil.
Oxford Nanopore Technologies's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2024 was -77.268 (Dec. 2023 ) + -59.971 (Jun. 2024 ) = £-137.2 Mil.
Oxford Nanopore Technologies's Cash Flow from Investing for the trailing twelve months (TTM) ended in Jun. 2024 was -102.664 (Dec. 2023 ) + 4.327 (Jun. 2024 ) = £-98.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oxford Nanopore Technologies (LSE:ONT) Sloan Ratio % Explanation
A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.
If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.
If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.
If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.
As of Jun. 2024, Oxford Nanopore Technologies has a Sloan Ratio of 10.59%, indicating there is a warning stage of accrual build up.
Oxford Nanopore Technologies Sloan Ratio % Related Terms
Thank you for viewing the detailed overview of Oxford Nanopore Technologies's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.
Oxford Nanopore Technologies PLC makes a novel generation of DNA/RNA sequencing technology that provides rich data and is fast, accessible, and easy to use. The company is predominantly involved in researching, developing, manufacturing, and commercializing a nanopore-based sequencing platform that allows the real-time analysis of deoxyribonucleic acid (DNA) or ribonucleic acid (RNA). This enables its customers to perform scientific/biomedical research in a range of areas, including human genetics, cancer research, outbreak surveillance, environmental analysis, pathogens/antimicrobial resistance, microbiome analysis, and crop science. The company's reportable segments are; Life Science Research Tools which generates key revenue, and COVID Testing.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LSE:ONT has been successfully added to your 